- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05892614
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
April 19, 2024 updated by: aTyr Pharma, Inc.
Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD.
The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD.
While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin.
After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including Week 20.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: aTyr Pharma Clinical Research
- Phone Number: 877-215-5731
- Email: clinicaltrials@atyrpharma.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- Not yet recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
San Diego, California, United States, 92093
- Not yet recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Florida
-
Miami, Florida, United States, 33146
- Not yet recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
Chicago, Illinois, United States, 60612
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
Chicago, Illinois, United States, 60153
- Not yet recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
New York
-
New York, New York, United States, 10027
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Texas
-
Dallas, Texas, United States, 75204
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
Houston, Texas, United States, 77204
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Virginia
-
Richmond, Virginia, United States, 23284
- Recruiting
- aTyr Investigative Site
-
Contact:
- Phone Number: 877-689-4494
- Email: SScILD@cssienroll.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of SSc based on ACR/ EULAR criteria (2013)
- Overall duration of SSc < 48 months from the first non-Raynaud symptom manifestation
- HRCT obtained at the Screening Visit or within the 3 months prior to Screening consistent with SSc-ILD (adjudicated by a central reader) AND with pulmonary involvement > 10%
- Clinical presentation at Screening consistent with lcSSc (up to 40% of patients) or dcSSc
Presence of at least:
Any 1 laboratory marker for active disease
OR
Clinically significant decline in FVC % predicted (%pred) based on ≥ 105% relative decline over the preceding one year (two readings from the same pulmonary function laboratory)
- MMF of ≥ 2 gm/day (or equivalent doses of other mycophenolate based compounds) for 6 months
Exclusion Criteria:
- Pulmonary disease with FVC %pred ≤ 45% OR DLco %pred ≤ 30%; FEV1/FVC ratio < 0.7
- Participants with pulmonary artery hypertension on parenteral therapy or with clinical evidence of right heart failure
- HRCT obtained in the 3 months prior to Screening consistent with other confounding pathology.
- Treatment with corticosteroids (> 10 mg/day of prednisone or equivalent) within 2 weeks prior to baseline
- SSc-ILD treatments other than MMF OR MMF < 2 gm/day
- Any previous treatment with any of the following: rituximab, intravenous immune globulin (IVIG), tocilizumab, cyclophosphamide, pirfenidone, tyrosine-kinase inhibitors (e.g., imatinib, nilotinib, dasatinib)
- Rheumatic autoimmune disease other than SSc, Is an active, heavy smoker of tobacco/nicotine-containing products
- History of (anti-Jo-1) anti-synthetase syndrome or Jo-1 positive at Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: efzofitimod 450 mg
Administered IV infusion
|
IV infusion over approximately 60 minutes every 4 weeks
|
Experimental: efzofitimod 270 mg
Administered IV infusion
|
IV infusion over approximately 60 minutes every 4 weeks
|
Placebo Comparator: Placebo
Administered IV infusion
|
IV infusion over approximately 60 minutes every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change from baseline in forced vital capacity (FVC) in mL
Time Frame: 24 weeks
|
24 weeks
|
Annual rate of decline in FVC in mL
Time Frame: 24 weeks
|
24 weeks
|
Annual rate of decline in FVC in percent predicted
Time Frame: 24 weeks
|
24 weeks
|
Proportion of patients with > 5% and ≥ 10% decline in absolute FVC
Time Frame: Baseline to week 24
|
Baseline to week 24
|
Proportion of patients with > 5% and ≥ 10% decline in percent predicted FVC
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Change in HRCT fibrosis score
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Lisa Carey, aTyr Pharma, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 12, 2023
First Submitted That Met QC Criteria
June 5, 2023
First Posted (Actual)
June 7, 2023
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATYR1923-C-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Lung Disease
-
Matthias GrieseSuspendedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationNot yet recruitingFibrotic Interstitial Lung Disease
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Heidelberg UniversityHelmholtz Zentrum München; University of Giessen; Lungenfibrose e.V.; German Center... and other collaboratorsCompletedInterstitial Lung Disease (ILD)Germany
-
University of California, San FranciscoTerminatedFibrotic Interstitial Lung DiseaseUnited States
-
University of AarhusAarhus University HospitalNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseDenmark
-
West Virginia UniversityNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseUnited States
-
Saglik Bilimleri UniversitesiRecruitingTelerehabilitation | Fibrosing Interstitial Lung DiseaseTurkey
Clinical Trials on efzofitimod 450 mg
-
aTyr Pharma, Inc.Foundation for Sarcoidosis ResearchCompletedPulmonary SarcoidosisUnited States
-
aTyr Pharma, Inc.Kyorin Pharmaceutical Co.,LtdRecruitingPulmonary SarcoidosisUnited States, Netherlands, Spain, United Kingdom, France, Italy, Brazil, Germany, Puerto Rico, Japan
-
aTyr Pharma, Inc.CompletedSARS-CoV-2 (COVID-19) Severe PneumoniaUnited States, Puerto Rico
-
Regeneron PharmaceuticalsCompletedHomozygous Familial HypercholesterolemiaUnited States, Netherlands, Canada
-
Oxford Cannabinoid Technologies Holdings PLCSimbec-Orion GroupCompleted
-
CytokineticsAstellas Pharma Global Development, Inc.CompletedSpinal Muscular AtrophyUnited States, Canada
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...RecruitingPulmonary Disease, Chronic ObstructiveChina
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesterolemia
-
Novartis PharmaceuticalsTerminatedAsthmaGermany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
-
The Cleveland ClinicBristol-Myers Squibb; National Institute of Allergy and Infectious Diseases... and other collaboratorsTerminatedHIV Infection | Mitochondrial DysfunctionUnited States